Silence Therapeutics (SLN) EBIAT: 2020-2025
Historic EBIAT for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$21.0 million.
- Silence Therapeutics' EBIAT rose 41.04% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 4.36%. This contributed to the annual value of -$45.3 million for FY2024, which is 16.45% up from last year.
- Latest data reveals that Silence Therapeutics reported EBIAT of -$21.0 million as of Q3 2025, which was up 23.38% from -$27.4 million recorded in Q2 2025.
- Over the past 5 years, Silence Therapeutics' EBIAT peaked at $12.3 million during Q4 2024, and registered a low of -$13.6 billion during Q1 2021.
- Moreover, its 3-year median value for EBIAT was -$15.4 million (2023), whereas its average is -$16.0 million.
- Its EBIAT has fluctuated over the past 5 years, first surged by 224.58% in 2024, then plummeted by 1,134.00% in 2025.
- Quarterly analysis of 5 years shows Silence Therapeutics' EBIAT stood at -$6.4 million in 2021, then tumbled by 48.71% to -$9.6 million in 2022, then decreased by 3.03% to -$9.9 million in 2023, then spiked by 224.58% to $12.3 million in 2024, then soared by 41.04% to -$21.0 million in 2025.
- Its EBIAT stands at -$21.0 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$28.5 million for Q1 2025.